These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 37406019)

  • 1. Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.
    Liu Y; Shen B; Huang T; Wang J; Jiang J
    PLoS One; 2023; 18(7):e0288013. PubMed ID: 37406019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma.
    Zhang X; Zheng P; Meng B; Zhuang H; Lu B; Yao J; Han F; Luo S
    Clin Exp Med; 2024 Jun; 24(1):129. PubMed ID: 38884870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
    Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
    Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
    Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
    Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
    Yan Z; He M; He L; Wei L; Zhang Y
    Front Immunol; 2021; 12():723271. PubMed ID: 34925311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
    Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
    BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
    Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Aging-Related Prognostic Signature Reveals the Landscape of the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Chen F; Gong X; Xia M; Yu F; Wu J; Yu C; Li J
    Front Oncol; 2022; 12():857994. PubMed ID: 35619896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].
    Rong HC; Zhao WF; Zheng N; Guo ZH; Wang YW; Huang XP
    Zhonghua Gan Zang Bing Za Zhi; 2023 May; 31(5):509-517. PubMed ID: 37365028
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients.
    Zhang B; Tang B; Gao J; Li J; Kong L; Qin L
    J Transl Med; 2020 Sep; 18(1):342. PubMed ID: 32887635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.
    Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G
    Front Immunol; 2022; 13():929089. PubMed ID: 35874689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
    Xu L; Zheng Q; Liu W
    BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
    Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
    J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.